EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)

SIMPLE SUMMARY: Pancreatic neuroendocrine neoplasms (PanNENs) represent 3% of pancreatic neoplasms. Available therapies can induce stable disease only for a minority of patients. Overall survival ranges from 10 years for well-differentiated neuroendocrine tumors to as little as 10 months for more ag...

Descripción completa

Detalles Bibliográficos
Autores principales: April-Monn, Simon Leonhard, Andreasi, Valentina, Schiavo Lena, Marco, Sadowski, Martin Carl, Kim-Fuchs, Corina, Buri, Michelle Claudine, Ketkar, Avanee, Maire, Renaud, Di Domenico, Annunziata, Schrader, Jörg, Muffatti, Francesca, Doglioni, Claudio, Partelli, Stefano, Falconi, Massimo, Perren, Aurel, Marinoni, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508156/
https://www.ncbi.nlm.nih.gov/pubmed/34638497
http://dx.doi.org/10.3390/cancers13195014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508156/
https://www.ncbi.nlm.nih.gov/pubmed/34638497
http://dx.doi.org/10.3390/cancers13195014

Ejemplares similares